In Qasim et al., PAKs 1 and 4 are associated with aggressive Ewing sarcoma and poor patient prognosis, and PAK4 inhibition is linked to decreased Ewing sarcoma cell viability, synergistic in vitro effects with chemotherapy agents, and decreased tumorigenic and metastatic potential in vivo. The gene discussed is PAK4; the disease is Ewing sarcoma.